Richard N Kolesnick

USPTO Granted Patents = 23 (Patent Applications = 15)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 2.4

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

New York City, NY (US) (2019 - 2022)
New York, NY (US) (1995 - 2024)

Company Filing History:

12 out of 559

Memorial Sloan Kettering Cancer Center

patents

7 out of 512

Sloan-kettering Institute for Cancer Research

patents

4 out of 5,444

University of Texas System

patents

4. 2 out of 2

Ceramide Therapeutics

patents

5. 2 out of 2,882

The General Hospital Corporation

patents

6. 1 out of 1,415

Michigan State University

patents

7. 1 out of 891

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

8. 1 out of 3

Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud

patents

9. 3 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12214218 - Perfusion modulated tumor dose sculpting with single dose radiotherapy (2025-02-04),

2. 12121525 - Methods for treating GI syndrome and graft versus host disease (2024-10-22),

3. 12036212 - Enhancement of tumor response to chemotherapy by activation of the asmase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent (2024-07-16),

4. 11447572 - Anti-ceramide antibodies (2022-09-20),

5. 11285137 - Enhancement of tumor response to chemotherapy by activation of the asmase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent (2022-03-29),

6. 11207329 - Methods for treating GI syndrome and graft versus host disease (2021-12-28),

7. 10975169 - Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 (2021-04-13),

8. 10722577 - Methods for treating GI syndrome and graft versus host disease (2020-07-28),

9. 10450385 - Anti-ceramide antibodies (2019-10-22),

10. 10413533 - Enhancement of tumor response to chemotherapy by activation of the ASMase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent (2019-09-17),

11. 10052387 - Ceramide reversal of multi-drug resistance (2018-08-21),

12. 9592238 - Anti-ceramide monoclonal antibody 2A2 (2017-03-14),

13. 8562993 - Methods for treating GI syndrome and graft versus host disease (2013-10-22),

14. 8283459 - Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis (2012-10-09),

15. 8258108 - Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis (2012-09-04),

Title: The Innovative Journey of Richard N Kolesnick

Introduction: Richard N Kolesnick is a renowned inventor based in New York, NY, known for his groundbreaking contributions to the field of science and technology.

Latest Patents: Richard N Kolesnick holds several patents in the areas of biotechnology and medical research, focusing on novel treatments for various diseases and conditions.

Career Highlights: With a distinguished career spanning over three decades, Richard N Kolesnick has made significant advancements in the fields of pharmacology and molecular biology. His work has led to the development of innovative therapies that have the potential to revolutionize healthcare.

Collaborations: Throughout his career, Richard N Kolesnick has collaborated with leading researchers, scientists, and medical professionals to further his research and bring his inventions to life. His collaborative efforts have resulted in groundbreaking discoveries that have garnered international recognition.

Conclusion: Richard N Kolesnick's relentless pursuit of innovation and his dedication to improving human health have solidified his reputation as a pioneering inventor in the scientific community. His contributions continue to inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.